Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

US FDA approves Lilly's breast cancer drug combo

18 September 2026 · By · Wire by Fusion42

Published

18 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at reuters.com →

◆ Verified

Fusion42 · 18 September 2026 · Fusion42 review

The US FDA approved Eli Lilly's combination of Inluriyo and Verzenio for adults with advanced estrogen receptor-positive, HER2-negative breast cancer with ESR1 mutations, improving progression-free survival.

This Wire brief sits within Fusion42's coverage of Biotech, and 5 sources have reported it between 18 Sep 2026 and 21 Sep 2026.

◆ ◆ The Wire takeaway

You can now target a critical breast cancer segment with a newly approved therapy combining Inluriyo and Verzenio that nearly doubles progression-free survival. This offers a fresh route into advanced oncology treatments requiring ESR1 mutation testing.

◆ Coverage

5 sources · first reported 18 Sep 2026 · latest 21 Sep 2026

◆ Related on Wire

◆ Topics

Biotechbreast-cancerfda-approvaldrug-combooncologylilly